drugset / Trial / NCT02447679
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
NaSingle-groupOpen-labelPrevention
Summary
This single-centered phase II clinical study is to obtain preliminary information on 1-year recurrence-free survival rate, recurrence-free survival and safety profile of thalidomide in combination with tegafur-uracil in hepatocellular carcinoma after hepatectomy and explore biomarkers(VEGF/bFGF) for thalidomide response.
Timeline
- Start
- 2010-08
- Primary completion
- 2017-01-31
- Completion
- 2017-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thalidomide | Other / unclassified | 400 mg | Oral |
| Background | tegafur-uracil | Small molecule | — | — |